Please ensure Javascript is enabled for purposes of website accessibility

NVIDIA's Relationship With Healthcare Is Worth More Than You Think

By Jeff Little – Apr 22, 2021 at 5:10AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NVIDIA's opportunities in gaming, enterprise graphics, datacenter, and auto are all great. But don't overlook healthcare.

Let me start with a few keywords that should grab the attention of any potential investor: artificial intelligence (AI), deep learning, augmented reality, and accelerated computing. With technology advancements in these areas, computers are learning to write their own software, images are clearer, and the medical world is moving like the Millennium Falcon with Han Solo at the helm.

When we take a look at how these areas are shaping our world, there's one name that is consistently at or near the top: NVIDIA (NVDA 2.60%). As a leader in innovative tech, from its GPUs that power gaming, enterprise graphics, and datacenters, to Jetson-like autonomous vehicles, the company has a hand in most things AI-related. But, did you know that NVIDIA's AI advancements also play an enormous part in the evolving healthcare industry? 

Two female and two male doctors in white coats sit around a table discussing data and medical scans.

Image source: Getty Images

The healthcare connection

During the annual GPU Technology Conference (GTC21) last week, NVIDIA shared over 200 presentations focused on healthcare, covering four primary areas: medical imaging, genomics, drug discovery, and smart hospitals. From kickoff to completion, NVIDIA leadership, along with its partners, drove home the importance of bringing AI and accelerated computing into surgery rooms, exam rooms, care centers, research labs, and reception areas. Advancements, such as NVIDIA Clara -- a framework application that provide tools to researchers and clinicians working in genomics, drug discovery, and medical device development -- are expanding, and bringing the medical world to the next level.

Moments in the sun

Fortunately, through the leadership of its Founder and CEO, Jensen Huang, NVIDIA has been successful in creating numerous pivotal moments to assist in revolutionizing technological advancement across the healthcare industry. Here are a few from the past five years:

  • 2017: GE Healthcare is the first medical device company to use the NVIDIA GPU Cloud
  • 2018: NVIDIA Clara platform introduced to bring AI to the next generation of medical instruments
  • 2019: NVIDIA's Tensor Core GPUs are used for genome sequencing acceleration, allowing for rapid speeds and lowering costs
  • 2020: NVIDIA debuts Clara Guardian to power smart hospitals; releases new AI models to help better detect infection; breaks genomics speed record in race to understand the SARS-CoV-2 virus
  • 2021: "We are seeing the smartphone moment for every industry" – Jensen Huang, referring to thousands of companies across the world applying NVIDIA AI to create cloud-connected products with AI services that will transform the world's largest industries

A sign of good things

The global AI market in healthcare is estimated to grow between 40% and 50% per year on a compounded annual growth rate (CAGR) through 2027 -- based on various reports -- for a market value just north of $60 billion. This leaves plenty of space for NVIDIA to collect outstanding revenues. And while sales are poised to explode, an analysis produced by Accenture finds that key clinical health AI applications could also create $150 billion in annual savings for the U.S. healthcare economy by 2026.

As the company continues to innovate, it will be helped along by the winds of change that take place within the healthcare space. As we've seen with response to the COVID-19 pandemic, it is increasingly important to diagnose serious ailments early, and to be able to model and predict results and outcomes. And as we continue to fight life-threatening diseases, more clinical trials will require applications that allow for deep learning at record speed with minimal human intervention.

In the next five to seven years, the healthcare industry is expected to grow rapidly in each of the four areas that were mentioned as primary segments for NVIDIA at this year's GTC21 event.

Market Segment Compound Annual Growth Rate (CAGR) % Through (Year)
Drug discovery 9.6 2025
Smart hospitals 21.1 2025
Medical imaging 5.2 2028
Genomics 15.4 2028

Sources: BCC Research, Grand View Research, GlobeNewswire

NVIDIA currently totes a price-to-earnings (P/E) ratio of 88, which some may see as a bit high, considering competitors like AMD, Google, IBM, and Microsoft all fall in a range between 22 and 38, with Intel on the lower end at 13. By comparison, the average stock on the S&P 500 trades for 47 times earnings. But then again, NVIDIA's higher ratio also reflects that investors are expecting higher growth. In this case, I think it's for good reason.

Consistency is key

Solid revenue growth and a 16% gain year to date on the stock price is a lot to get excited about. In fact, even when the market experiences downturns as a whole, NVIDIA is still taking care of its investors, as exemplified by 34 straight quarters of dividend payouts dating back to 2012 -- and increasing every year since -- to a most recent annual payout of $0.64 per share.

And at no time did the dividend ever decrease during the course of a calendar year in that span. That is proof of consistency. One might conclude, after 10 quarters at $0.16, and following an excellent fourth quarter earnings call -- revenues jumped 61% year over year and beat estimates by 3.6% -- it may not take long to see that quarterly dividend go up a bit at some point before the year is over. That would be music to any investor's ears, and the sheer potential presented by the future of healthcare computing should justify NVIDIA as a company to consider for your portfolio.

Jeff Little owns shares of NVIDIA. Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. The Motley Fool owns shares of and recommends Accenture, Alphabet (A shares), Alphabet (C shares), Microsoft, and NVIDIA. The Motley Fool recommends Intel and recommends the following options: long January 2023 $57.5 calls on Intel and short January 2023 $57.5 puts on Intel. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NVIDIA Corporation Stock Quote
NVIDIA Corporation
NVDA
$127.36 (2.60%) $3.23
International Business Machines Corporation Stock Quote
International Business Machines Corporation
IBM
$122.76 (0.84%) $1.02
General Electric Company Stock Quote
General Electric Company
GE
$64.46 (-0.02%) $0.01
Microsoft Corporation Stock Quote
Microsoft Corporation
MSFT
$241.07 (1.97%) $4.66
Alphabet Inc. Stock Quote
Alphabet Inc.
GOOGL
$100.05 (2.62%) $2.55
Intel Corporation Stock Quote
Intel Corporation
INTC
$27.13 (0.89%) $0.24
Advanced Micro Devices, Inc. Stock Quote
Advanced Micro Devices, Inc.
AMD
$68.36 (1.77%) $1.19
Accenture plc Stock Quote
Accenture plc
ACN
$261.93 (2.18%) $5.59
Alphabet Inc. Stock Quote
Alphabet Inc.
GOOG
$100.74 (2.70%) $2.65

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.